guttitude logo

guttitude

early access
Get Checklistguttitude Pro
← Back to atlas
fulltoplow inflation risk

Akkermansia muciniphila

autism

Akkermansia muciniphila looks like a credible signal in autism, though some caution is still warranted.

Akkermansia muciniphila shows a strong literature footprint in autism, with substantial central evidence and broader supporting literature.

akkermansia_muciniphila
Credibility score
64
Human translation
3/5
Reproducibility
4/5
Novelty
2/5
Actionability
4/5
Credibility 64Human translation 3/5Reproducibility 4/5Novelty 2/5Actionability 4/5
Why this scores the way it does
  • strong central evidence base
  • dense review literature
  • substantial preclinical support
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

19 papers
Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism.
2011
Applied and environmental microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified.
2013
PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Changes in the Gut Microbiota of Children with Autism Spectrum Disorder.
2020
Autism research : official journal of the International Society for Autism Research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The effect of fecal microbiota transplantation on autistic-like behaviors in Fmr1 KO mice.
2020
Life sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comparison of gut microbiota in autism spectrum disorders and neurotypical boys in China: A case-control study.
2021
Synthetic and systems biotechnology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Commercial microbiota test revealed differences in the composition of intestinal microorganisms between children with autism spectrum disorders and neurotypical peers.
2021
Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Different Alterations in Gut Microbiota between Bifidobacterium longum and Fecal Microbiota Transplantation Treatments in Propionic Acid Rat Model of Autism.
2022
Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A Computational Framework for Studying Gut-Brain Axis in Autism Spectrum Disorder.
2022
Frontiers in physiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Associations Between Gut Microbes and Social Behavior in Healthy 2-Year-Old Children.
2022
Psychosomatic medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases.
2023
Journal of Alzheimer's disease : JAD
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A Two-Step Single Plex PCR Method for Evaluating Key Colonic Microbiota Markers in Young Mexicans with Autism Spectrum Disorders: Protocol and Pilot Epidemiological Application.
2023
Diagnostics (Basel, Switzerland)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Infant microbes and metabolites point to childhood neurodevelopmental disorders.
2024
Cell
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Analysis of Gut Bacterial and Fungal Microbiota in Children with Autism Spectrum Disorder and Their Non-Autistic Siblings.
2024
Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Omic characterizing and targeting gut dysbiosis in children with autism spectrum disorder: symptom alleviation through combined probiotic and medium-carbohydrate diet intervention - a pilot study.
2024
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota and its influence on the Gut-Brain axis in comparison with chemotherapy patients and cancer-free control data in Breast cancer-A computational perspective.
2025
PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota characteristics and therapeutic effects of fecal microbiota transplantation in children with autism spectrum disorder in central China: a combined cross-sectional and prospective study.
2025
Frontiers in pediatrics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Lacticaseibacillus rhamnosus GR-1 prevents autism-like behaviors by reshaping the maternal and offspring microbiome.
2025
NPJ biofilms and microbiomes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota transplantation and Akkermansia muciniphila restore neurodevelopment and behavior via the gut-brain axis in autism-like zebrafish.
2026
The ISME journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota and its association with gastrointestinal symptoms and pharmacological treatments in a sibling-matched cohort with autism spectrum disorder.
2026
Frontiers in microbiomes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Supporting primary evidence

1 papers
The Difference of Gut Microbiota and Their Correlations With Urinary Organic Acids Between Autistic Children With and Without Atopic Dermatitis.
2022
Frontiers in cellular and infection microbiology
Human primary paper with plausible association relevance to the disease context.

Preclinical supporting evidence

11 papers
Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder.
2016
Molecular autism
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Analysis of gut microbiome, nutrition and immune status in autism spectrum disorder: a case-control study in Ecuador.
2020
Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Anxiety-like behavior and intestinal microbiota changes as strain-and sex-dependent sequelae of mild food allergy in mouse models of cow's milk allergy.
2021
Brain, behavior, and immunity
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Altered Gut Microbiota in a Fragile X Syndrome Mouse Model.
2021
Frontiers in neuroscience
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
2022
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Ketogenic diet ameliorates autism spectrum disorders-like behaviors via reduced inflammatory factors and microbiota remodeling in BTBR T+ Itpr3tf/J mice.
2023
Experimental neurology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Maternal exposure of mice to glyphosate induces depression- and anxiety-like behavior in the offspring via alterations of the gut-brain axis.
2023
The Science of the total environment
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium animalis subsp. lactis Probio-M8 alleviates abnormal behavior and regulates gut microbiota in a mouse model suffering from autism.
2024
mSystems
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Mice expressing the autism-associated neuroligin-3 R451C variant exhibit increased mucus density and altered distributions of intestinal microbiota.
2025
The ISME journal
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Supplementation of 2'-Fucosyllactose during the Growth Period Improves Neurodevelopmental Disorders in Offspring Mice Induced by Maternal Immune Activation.
2025
Journal of agricultural and food chemistry
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intermittent Fasting and Akkermansia muciniphila Exert Independent and Combined Benefits on Behavioral and Neurobiological Deficits in a VPA-Induced Autism Rat Model.
2026
Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

13 papers
Association Between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.
2019
Frontiers in psychiatry
Relevant review or meta-analysis for the signal-disease area.
Engineered Akkermansia muciniphila: A promising agent against diseases (Review).
2020
Experimental and therapeutic medicine
Relevant review or meta-analysis for the signal-disease area.
Comparing the Gut Microbiome in Autism and Preclinical Models: A Systematic Review.
2022
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Profiles in Children and Adolescents with Psychiatric Disorders.
2022
Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota, the Potential Biological Medicine for Prevention, Intervention and Drug Sensitization to Fight Diseases.
2022
Nutrients
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila in neuropsychiatric disorders: friend or foe?
2023
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review.
2023
Nutrients
Relevant review or meta-analysis for the signal-disease area.
Early-Life Microbiome and Neurodevelopmental Disorders: A Systematic Review and Meta-Analysis.
2026
Current neuropharmacology
Relevant review or meta-analysis for the signal-disease area.
Perturbations in gut microbiota in autism spectrum disorder: a systematic review.
2025
Frontiers in neuroscience
Relevant review or meta-analysis for the signal-disease area.
Neurodevelopmental disorders and gut-brain interactions: exploring the therapeutic potential of pycnogenol through microbial-metabolic-neural networks.
2025
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
The endocannabinoidome-gut microbiome-brain axis as a novel therapeutic target for autism spectrum disorder.
2025
Journal of biomedical science
Relevant review or meta-analysis for the signal-disease area.
Akkermansia muciniphila in neurological disorders: mechanisms and therapeutic potential via the gut-brain axis.
2025
Frontiers in neuroscience
Relevant review or meta-analysis for the signal-disease area.
Microbial dysbiosis as a diagnostic marker in psychiatric disorders: a systematic review of gut-brain axis disruptions.
2026
Frontiers in neuroscience
Relevant review or meta-analysis for the signal-disease area.